Analysis of differential BRAFV600E mutational status in multifocal papillary thyroid carcinoma: Evidence of independent clonal origin in distinct tumor foci

Cancer

Volumn 107, Issue 8, 2006, Pages 1831-1838

  Park, So Yeon ^a,b   Park, Young Joo ^a,b   Lee, Yu Jin ^b   Lee, Hyun Sook ^c   Choi, Sung Hee ^a,b   Choe, Gheeyoung ^a,b   Jan, Hak Chul ^a,b   Park, Seong Hoe ^b   Park, Do Joon ^b,c   Cho, Bo Youn ^b,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

BRAFV600E mutation; Multifocal papillary cancers; Papillary thyroid cancers

Indexed keywords

B RAF KINASE;

ADULT; ARTICLE; BRAF GENE; CANCER GENETICS; DNA ISOLATION; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SUBTOTAL THYROIDECTOMY; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADULT; CARCINOMA, PAPILLARY; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 33750062281     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22218     Document Type: Article

References (30)

1. Iida F, Yonekura M, Miyakawa M. Study of intraglandular dissemination of thyroid cancer. Cancer. 1969;24:764-771.
2. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55:805-828.
3. Russell WO, Ibanez ML, Clark RL, White EC. Thyroid carcinoma classification, intraglandular dissemination, and clinicopathological study based upon whole organ section of 80 glands. Cancer. 1963;16:1425-1460.
4. Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma: a clinicopathologic study of 105 consecutive patients. Cancer. 1992;70:1585-1590.
5. Mazzaferri EL, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
6. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment. Initial analysis of staging and outcome. Cancer. 1998;83:1012-1021.
7. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83:4116-4122.
8. Moniz S, Catarino AL, Marques AR, Cavaco B, Sobrinho L, Leite V. Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur J Endocrinol. 2002;146:27-33.
9. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005;352:2406-2412.
10. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-563.
11. Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of RET protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 1994; 54:2979-2985.
12. Pierotti MA, Bongarzone I, Borrello MG, et al. Rearrangements of TRK protooncogene in papillary thyroid carcinomas. J Endocrinol Invest. 1995;18:130-133.
13. Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998;154:237-247.
14. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
15. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455-6457.
16. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
17. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567.
18. Chung JH, Hahm JR, Min YK, et al. Detection of RET/PTC oncogene rearrangements in Korean papillary thyroid carcinomas. Thyroid. 1999;9:1237-1243.
19. Chung KW, Chang MC, Noh DY, Oh SK, Choe KJ, Yoon YK. RET oncogene expression of papillary thyroid carcinoma in Korea. Surg Today. 2004;34:485-492.
20. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818-821.
21. Rosai J, Carcangiu ML, DeLellisn RA. Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1992.
22. Reinhoff WF Jr. Lymphatic vessels of thyroid gland in dog and man. Arch Surg. 1931;23:783-804.
23. Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer. 2002;94:1910-1916.
24. Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990;86:120-125.
25. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995;95:2047-2053.
26. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238-4245.
27. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
28. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with histologic types of papillary thyroid carcinoma. J Pathol. 2004;202:247-251.
29. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005;446:589-595.
30. Sedliarou I, Saenko V, Lantsov D, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004;25:1729-1735.